Patents by Inventor Zhijian Lu

Zhijian Lu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11008313
    Abstract: The present invention relates to PCSK9 allosteric binding compounds of Formula I: (Formula (I)) and pharmaceutically acceptable salts thereof, wherein X1, X2, Y, R1, R2, RA, RB and n are as defined herein. The present invention also relates to compositions which comprise an allosteric binding compound of the invention or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. The invention further relates, inter alia, to methods for inducing PCSK9 protein degradation in a subject, and methods for treating atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions, comprising administering to a subject an effective amount of a compound or a pharmaceutically acceptable salt of the invention. The invention also provides a means for the in vitro labeling, detection and/or quantification of PCSK9 in biological samples.
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: May 18, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jason Eugene Imbriglio, Whitney Lane Petrilli, Yusheng Xiong, Zhe Feng, Hyewon Youm, Wonsuk Chang, Rui Liang, Zhijian Lu, Jerry Andrew Taylor, Scott B. Hoyt
  • Patent number: 11008361
    Abstract: Disclosed herein are a liver specific delivery (LSD)-based antiviral prodrug nucleoside cyclophosphate compound and uses thereof. Specifically, this application provides a compound of formula (I), or an isomer, a pharmaceutically acceptable salt, a hydrate, a solvate or a pharmaceutical composition thereof. This application also provides an application of the compound alone or in combination with other antiviral drugs in the treatment for viruses, particularly hepatitis C virus (HCV).
    Type: Grant
    Filed: October 18, 2019
    Date of Patent: May 18, 2021
    Assignee: ZHEJIANG PALO ALTO PHARMACEUTICALS, INC.
    Inventors: Zhijian Xi, Huaqiang Xu, Chunping Lu, Zhongshan Wu, Feng Sun
  • Publication number: 20210127923
    Abstract: The present disclosure provides a cleaning system, comprising a cleaning robot and a processing station. The cleaning robot comprises a machine body, a trash discharging port and a sealing mechanism provided at the bottom of the machine body, and the sealing mechanism is configured to seal the trash discharging port. The processing station comprises a controller, an electromagnet, and a signal guiding component. The signal guiding component is configured to guide the cleaning robot to dock with the processing station, and the controller is configured to detect induction information on the processing station and control the electromagnet according to the induction information to generate a magnetic force to attract the sealing mechanism to open the trash discharging port.
    Type: Application
    Filed: August 25, 2020
    Publication date: May 6, 2021
    Inventors: ZHIJIAN LIANG, QUANLONG LU
  • Publication number: 20210121458
    Abstract: Bruton's tyrosine kinase (Btk) inhibitors have the following Formula (I):
    Type: Application
    Filed: January 1, 2021
    Publication date: April 29, 2021
    Inventors: Xibin LIAO, Jia LI, Zhijian LU, Yubo ZHOU, Anhui GAO
  • Publication number: 20210107903
    Abstract: Bruton's tyrosine kinase (Btk) inhibitors have the following Formula (I):
    Type: Application
    Filed: March 21, 2018
    Publication date: April 15, 2021
    Inventors: Xibin LIAO, Jia LI, Zhijian LU, Yubo ZHOU, Anhui GAO
  • Patent number: 10933063
    Abstract: Bruton's tyrosine kinase (Btk) inhibitors have the following Formula (I):
    Type: Grant
    Filed: May 22, 2019
    Date of Patent: March 2, 2021
    Assignees: Suzhou Baijibugong Pharmaceutical Technology Co., Ltd.
    Inventors: Xibin Liao, Jia Li, Zhijian Lu, Yubo Zhou, Anhui Gao
  • Patent number: 10923938
    Abstract: A charging device for charging an electric energy storage device includes a power supply circuit connected to a power supply, an alternating current conversion circuit configured to convert a current from the power supply connected to the power supply circuit to a first alternating current with a preset frequency value, a transformer configured to convert the first alternating current to a second alternating current, wherein a voltage value corresponding to the second alternating current being less than a voltage value corresponding to the first alternating current, and a direct current voltage conversion circuit configured to convert the second alternating current to a direct current with a waveform fluctuating in a preset range, so as to charge an electric energy storage device.
    Type: Grant
    Filed: June 21, 2018
    Date of Patent: February 16, 2021
    Assignee: Nanjing Chervon Industry Co., Ltd.
    Inventors: Dezhong Yang, Yingdian Xiang, Hong Zhu, Zhijian Lu
  • Publication number: 20200369657
    Abstract: The present invention relates to PCSK9 allosteric binding compounds of Formula I: (Formula (I)) and pharmaceutically acceptable salts thereof wherein X1, X2, Y, R1, R2, RA, RB and n are as defined herein. The present invention also relates to compositions which comprise an allosteric binding compound of the invention or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. The invention further relates, inter alia, to methods for inducing PCSK9 protein degradation in a subject, and methods for treating atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions, comprising administering to a subject an effective amount of a compound or a pharmaceutically acceptable salt of the invention. The invention also provides a means for the in vitro labeling, detection and/or quantification of PCSK9 in biological samples.
    Type: Application
    Filed: September 15, 2017
    Publication date: November 26, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Jason Eugene Imbriglio, Whitney Lane Petrilli, Yusheng Xiong, Zhe Feng, Hyewon Youm, Wonsuk Chang, Rui Liang, Zhijian Lu, Jerry Andrew Taylor, Scott B. Hoyt
  • Patent number: 10793566
    Abstract: Bruton's tyrosine kinase (Btk) inhibitors have the following Formula (I):
    Type: Grant
    Filed: May 22, 2019
    Date of Patent: October 6, 2020
    Assignees: ZIBO BIOPOLAR CHANGSHENG PHARMACEUTICAL CO. LTD., SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Xibin Liao, Jia Li, Zhijian Lu, Yubo Zhou, Anhui Gao
  • Publication number: 20200304032
    Abstract: A power supply device and a booster circuit for a power supply device. The booster circuit includes an access terminal configured to access a direct current voltage from a battery pack, a transformer group electrically connected to the access terminal so that the accessed direct current voltage is boosted to a predetermined voltage by the transformer group, and a rectifier bridge electrically connected to the transformer group to convert the predetermined voltage into a high-voltage direct current after pulse rectification. The transformer group includes a first transformer including a first primary side and a first secondary side and a second transformer including a second primary side and a second secondary side. The power supply device disclosed is compact in structure and convenient to carry and can output an alternating current.
    Type: Application
    Filed: June 5, 2020
    Publication date: September 24, 2020
    Inventors: Hong Zhu, Zhijian Lu, Qing Gao
  • Patent number: 10784892
    Abstract: An apparatus includes a first memory interface circuit and a decompression circuit coupled to the first memory interface circuit. The decompression circuit may be configured to (i) receive a reduced size representation of a coding block of data comprising a first bit map, a second bit map, and zero or more non-zero values from an external memory via the first memory interface circuit, (ii) losslessly restore the coding block of data from the reduced size representation of the coding block using the first bit map, the second bit map, and the zero or more non-zero values, and (iii) transfer the restored coding block of data to a processing circuit.
    Type: Grant
    Filed: July 30, 2019
    Date of Patent: September 22, 2020
    Assignee: Ambarella International LP
    Inventors: Junqiang Lan, Zhijian Lu
  • Patent number: 10662187
    Abstract: Bruton's tyrosine kinase (Btk) inhibitors have the following Formula (I):
    Type: Grant
    Filed: January 17, 2017
    Date of Patent: May 26, 2020
    Assignees: Zibo Biopolar Changsheng Pharmaceutical Co. Ltd., Shanghai Institute of Materia Medica, Chinese Academy of Sciences
    Inventors: Xibin Liao, Jia Li, Zhijian Lu, Yubo Zhou, Anhui Gao
  • Publication number: 20190275037
    Abstract: Bruton's tyrosine kinase (Btk) inhibitors have the following Formula (I):
    Type: Application
    Filed: May 22, 2019
    Publication date: September 12, 2019
    Inventors: Xibin LIAO, Jia LI, Zhijian LU, Yubo ZHOU, Anhui GAO
  • Publication number: 20190276453
    Abstract: Bruton's tyrosine kinase (Btk) inhibitors have the following Formula (I):
    Type: Application
    Filed: May 22, 2019
    Publication date: September 12, 2019
    Inventors: Xibin LIAO, Jia LI, Zhijian LU, Yubo ZHOU, Anhui GAO
  • Patent number: 10411727
    Abstract: An apparatus includes a first memory interface circuit, a second memory interface circuit, and a compression circuit coupled between the first memory interface circuit and the second memory interface circuit. The compression circuit may be configured to receive a coding block of data via the first memory interface circuit, generate a reduced size representation of the coding block, and write the reduced size representation of the coding block to an external memory using the second memory interface circuit. The reduced size representation of said coding block generally comprises a first bit map, a second bit map, and zero or more non-zero values.
    Type: Grant
    Filed: October 10, 2018
    Date of Patent: September 10, 2019
    Assignee: Ambarella, Inc.
    Inventors: Junqiang Lan, Zhijian Lu
  • Publication number: 20190233777
    Abstract: The present invention provides a microemulsion remover comprising, based on the total weight of the microemulsion remover, 1) from 10% to 60%, at least one organic solvent, ii) from 10% to 50%, at least one co-solvent, iii) from 0.1% to 10%, at least one base, iv) from 0.1% to 10%, at least one oxidizer, v) from 0.1% to 10%, at least one surfactant, and vi) water.
    Type: Application
    Filed: January 30, 2018
    Publication date: August 1, 2019
    Inventors: Adam K. Schmitt, Carol E. Mohler, Kathleen M. O'Connell, Christopher J. Tucker, Zhijian Lu, Shintaro Yamada
  • Patent number: 10358446
    Abstract: Bruton's tyrosine kinase (Btk) inhibitors have the following Formula (I):
    Type: Grant
    Filed: October 3, 2016
    Date of Patent: July 23, 2019
    Assignees: ZIBO BIOPOLAR CHANGSHENG PHARMACEUTICAL CO., LTD., SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Xibin Liao, Jia Li, Zhijian Lu, Yubo Zhou, Anhui Gao
  • Publication number: 20190062328
    Abstract: Bruton's tyrosine kinase (Btk) inhibitors have the following Formula (I):
    Type: Application
    Filed: January 17, 2017
    Publication date: February 28, 2019
    Inventors: Xibin LIAO, Jia LI, Zhijian LU, Yubo ZHOU, Anhui GAO
  • Publication number: 20190044364
    Abstract: A charging device for charging an electric energy storage device includes a power supply circuit connected to a power supply, an alternating current conversion circuit configured to convert a current from the power supply connected to the power supply circuit to a first alternating current with a preset frequency value, a transformer configured to convert the first alternating current to a second alternating current, wherein a voltage value corresponding to the second alternating current being less than a voltage value corresponding to the first alternating current, and a direct current voltage conversion circuit configured to convert the second alternating current to a direct current with a waveform fluctuating in a preset range, so as to charge an electric energy storage device.
    Type: Application
    Filed: June 21, 2018
    Publication date: February 7, 2019
    Inventors: Dezhong Yang, Yingdian Xiang, Hong Zhu, Zhijian Lu
  • Patent number: 10131660
    Abstract: Certain tetrahydro-azepinoquinolines of structural formula I are agonists of the mammalian 5-HT2c receptor, and, in particular, are selective agonists of the mammalian 5-HT2c receptor. The compounds of the present invention are therefore useful for the treatment, control, or prevention of diseases, conditions, or disorders responsive to stimulation of the 5-HT2c receptor, such as obesity, obesity-related conditions, and certain CNS-related disorders, including schizophrenia and depression. They are also useful as aids for tobacco smoking cessation.
    Type: Grant
    Filed: August 26, 2015
    Date of Patent: November 20, 2018
    Assignee: Sunnylife Pharma, Inc.
    Inventors: Jonathan A. Groeper, Xibin Liao, Zhijian Lu